pharmaphorum January 6, 2022
Sarah Rickwood

In the second part of our examination of issues that will shape the course of 2022, we’ll update the ongoing impacts of the pandemic, which have, as they did in 2021, a pervasive effect on both pharma and healthcare issues, with themes we highlighted at the beginning of 2021 continuing their impact.

Big Tech makes significant healthcare moves

That Big Tech is planning significant moves into healthcare in 2022 is not a new phenomenon. However, what makes 2022 different in this respect is Big Tech’s positioning to ride the trends of healthcare digitisation, remote delivery and data utilisation, which have been started or accelerated by the COVID-19 pandemic.

With former Johnson&Johnson CEO Alex Gorsky, joining Apple’s board in November 2021...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech, Technology, Trends
Akiko Iwasaki: The Immunology of Covid and the Future
Novartis to acquire radiopharmaceutical firm Mariana Oncology for up to $1.75B
GLP-1 Agonists May One Day Treat Prostate Cancer
Amgen shares soar as executives outline obesity drug push
BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders

Share This Article